← Markets

Phathom Pharmaceuticals, Inc.

PHAT · NASDAQ

Market closed$10.94$-0.030000 (-0.27%)After hours $10.94 · 0.00%

Key statistics

Previous close$10.97
Open$10.82
Day high$11.33
Day low$10.82
52-week high$18.31
52-week low$7.61
Market cap872.53M
Volume480.19K
Average volume1.24M
P/E ratio-7.44
Forward P/E—
EPS-1.47
Dividend yield0.00%

Market context

Why it moved

PHAT experienced a modest decline today amid a lack of significant company-specific catalysts, with the minor pullback likely reflecting routine profit-taking and broader market hesitancy as prices retreated slightly from the day's high.

GovinfoGovInstagramCedclinicInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Phathom Pharmaceuticals closed essentially flat as the broader healthcare sector faced modest pressure amid a risk-off market day driven by escalating U.S.-Iran tensions and renewed concerns about AI spending sustainability. The stock remains caught between divided analyst sentiment — a recent Seeking Alpha downgrade to Sell citing flat Q1 sequential revenue growth, tegoprazan competition from Sebela, and a 2033 patent cliff, versus bullish views pointing to a path toward 2026 profitability and VOQUEZNA's ongoing clinical momentum highlighted at Digestive Disease Week. UBS's upgrade of the healthcare sector as a key allocation theme amid improving biotech M&A conditions offers a constructive backdrop.

-0.2735

July 17, 2026Phathom Pharmaceuticals closed modestly lower as the broader market faced tech-driven headwinds, with the S&P 500 and Nasdaq retreating on chip stock weakness. Investor focus for Phathom remains on the competitive dynamics around VOQUEZNA (vonoprazan), with a recent Seeking Alpha downgrade to Sell citing flat Q1 sequential revenue growth, mounting competition from Sebela's tegoprazan, and a 2033 patent cliff — offsetting analyst optimism around a potential 2026 profitability inflection. After-hours activity has the stock rebounding ~2.7%, suggesting some investor interest ahead of what could be a pivotal second half for the company's path to cash generation.

-0.724

June 24, 2026Phathom Pharmaceuticals closed modestly higher, outperforming a tech-led broad market selloff that pushed the Nasdaq down roughly 2%, as the company announced it completed enrollment ahead of schedule in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) for eosinophilic esophagitis. The study enrolled 95 adults across 41 U.S. sites, with topline data expected in Q4 2026—marking the first large placebo-controlled acid suppression trial in EoE. The clinical milestone adds to a constructive backdrop that includes a Q1 EPS beat, 150% trailing revenue growth, H.C. Wainwright's reiterated Buy rating with a $26 price target, and InvestingPro analysis suggesting the stock trades below fair value.

1.5903

GlobeNewswire · June 23, 2026Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)Investing.com · April 30, 2026Phathom Q1 2026 slides: revenue doubles, profitability in sightGlobeNewswire · April 30, 2026Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateQuiver Quantitative · October 20, 2025Phathom Pharmaceuticals to Hold Conference Call for Q3 2025 Financial Results and Business Update on October 30
Mt Newswire · June 23, 2026Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
Benzinga · June 23, 2026Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults
Benzinga · April 30, 2026Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga · April 30, 2026Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est
Benzinga · April 30, 2026Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate
Mt Newswire · April 30, 2026Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q1 Product Revenue $58.3M, vs. FactSet Est of $55.9M
Mt Newswire · April 30, 2026Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q1 Adjusted Loss $0.18 per Share, vs. FactSet Est of $-0.21
Benzinga · March 27, 2026Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18

Peers

S&P 500SPX · $7,457.69-1.01%Relay Therapeutics, Inc.RLAY · $19.91+2.79%Organon & Co.OGN · $13.52+0.22%Adaptive Biotechnologies CorporationADPT · $22.92+3.71%Theravance Biopharma IncTBPH · $16.93-0.24%Arvinas, Inc.ARVN · $8.01-0.25%Rapport Therapeutics, Inc. Common StockRAPP · $42.62+6.20%Evolus, Inc.EOLS · $5.73+1.78%Ironwood Pharmaceuticals, Inc.IRWD · $3.86-0.26%Arcutis Biotherapeutics, Inc.ARQT · $28.49+2.70%Alumis Inc.ALMS · $28.66+5.25%Incyte CorporationINCY · $117.25+0.51%